By Fineline Cube China’s National Medical Products Administration (NMPA) has granted approval to Hangzhou Biosunpharma Co., Ltd. for bewintinib, a novel JAK2 inhibitor, as first-line treatment for adult patients with intermediate-2 or high-risk myelofibrosis, including primary myelofibrosis (PMF), polycythemia vera–related myelofibrosis (PPV-MF), and essential thrombocythemia–related myelofibrosis (PET-MF).
Regulatory Approval Details
| Component | Specification |
|---|---|
| Regulatory Authority | National Medical Products Administration (NMPA) |
| Approval Timing | Late April 2026 |
| Indication | First-line treatment of intermediate-2/high-risk myelofibrosis |
| Patient Population | Adult patients with PMF, PPV-MF, or PET-MF |
| Treatment Goals | Address disease-related splenomegaly and improve disease-related symptoms |
| Drug Class | JAK2 inhibitor |
This approval marks bewintinib as the first domestically developed JAK2 inhibitor approved in China for myelofibrosis, addressing a significant unmet need in this rare hematologic malignancy.
Clinical Trial Results – Phase II/III Pivotal Data
| Endpoint | Bewintinib Group | Control Group | Between-Group Difference |
|---|---|---|---|
| SVR35 at 24 Weeks | 62.8% | 14.3% | +48.5 percentage points |
| Primary Endpoint | ≥35% reduction in spleen volume from baseline | Reference | Statistically significant |
| Safety Profile | Manageable | – | Consistent with JAK inhibitor class |
The pivotal Phase II/III trial demonstrated exceptional efficacy with 62.8% of patients achieving the primary endpoint of ≥35% spleen volume reduction (SVR35) after 24 weeks of treatment, representing a substantial 48.5 percentage point improvement over the control group.
Disease Background & Unmet Need
Myelofibrosis Overview:
- Prevalence: Rare myeloproliferative neoplasm affecting approximately 16,000-18,000 patients in China
- Disease Burden: Characterized by bone marrow fibrosis, splenomegaly, and debilitating constitutional symptoms
- Risk Stratification: Intermediate-2 and high-risk patients have median survival of 2-5 years without effective treatment
- Current Treatment Landscape: Limited options with existing JAK inhibitors primarily imported and costly
Bewintinib’s approval provides Chinese patients with access to an effective, locally developed treatment option that addresses both splenomegaly and symptom burden.
Market Impact & Strategic Significance
- Domestic Innovation: Represents China’s growing capability in developing targeted therapies for rare diseases
- Pricing Advantage: Potential for more accessible pricing compared to imported JAK inhibitors
- Clinical Differentiation: 62.8% SVR35 response rate positions bewintinib competitively in the global JAK inhibitor landscape
- Commercial Opportunity: Addresses underserved myelofibrosis patient population in China’s large healthcare market
- Regulatory Precedent: Demonstrates NMPA’s support for innovative domestic oncology/hematology development
Forward-Looking Statements
This brief contains forward-looking statements regarding commercial performance and market adoption. Actual results may differ due to competitive dynamics, pricing negotiations, and real-world clinical outcomes.-Fineline Info & Tech